Trial Profile
Activity and Safety of Everolimus in Combination With Octreotide LAR and Metformin in Patients With Advanced Pancreatic Well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, Open, Monocentric, Prospective Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Metformin; Octreotide
- Indications Pancreatic cancer; Primitive neuroectodermal tumours
- Focus Therapeutic Use
- Acronyms MetNET1
- 03 Sep 2021 Planned End Date changed from 1 Jun 2021 to 1 Oct 2021.
- 03 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2021 Planned End Date changed from 1 Jun 2017 to 1 Jun 2021.